SGLT2 (sodium-glucose cotransporter 2) inhibitors produce a distinctive pattern of benefits
on the evolution and progression of cardiomyopathy and nephropathy, which is …

SGLT2 inhibitors are antihyperglycemic drugs that protect kidneys and the heart of patients
with or without type 2 diabetes and preserved or reduced kidney function from failing. The …

Abstract Sodium–glucose cotransporter 2 (SGLT2) inhibitors reduce heart failure events by
direct action on the failing heart that is independent of changes in renal tubular function. In …

Ketone bodies play significant roles in organismal energy homeostasis, serving as oxidative
fuels, modulators of redox potential, lipogenic precursors, and signals, primarily during …

Sodium glucose cotransporter 2 inhibitors (SGLT2i) constitute a promising drug treatment for
heart failure patients with either preserved or reduced ejection fraction. Whereas SGLT2i …

Background Metabolic syndrome and related metabolic disturbances represent a state of
low-grade inflammation, which accelerates insulin resistance, type 2 diabetes (T2D) and …

Cardiovascular diseases (CVDs) such as atherosclerosis, myocardial remodeling,
myocardial ischemia-reperfusion (I/R) injury, heart failure, and oxidative stress are among …

Abstract Sodium-glucose cotransporter 2 (SGLT2) inhibitors have evident cardiovascular
benefits in patients with type 2 diabetes with or at high risk for atherosclerotic cardiovascular …

Inflammation promotes the development of heart failure (HF). The inflammasome is a
multimeric protein complex that plays an essential role in the innate immune response by …

Obesity, diabetes mellitus (mostly type 2), and COVID-19 show mutual interactions because
they are not only risk factors for both acute and chronic COVID-19 manifestations, but also …